Bristol-Myers Squibb Co. missed in its effort to show PD-1 inhibitor Opdivo could improve upon standard-of-care Nexavar in first-line hepatic cell carcinoma (HCC), leaving the pharma to look for a combination regimen with CTLA-4 inhibitor Yervoy in previously treated patients, as well as monotherapy in adjuvant care.
BMS' Bid For Opdivo In First-Line HCC Stymied
Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.
More from Immuno-oncology
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
More from Anticancer
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.